Core Insights - Company announced the presentation of preclinical research results for its key product CS2009 at the 2025 AACR annual meeting, focusing on a tri-specific antibody targeting PD-1, VEGFA, and CTLA-4 [1] - CS2009 is currently undergoing a global multi-center Phase I clinical trial in Australia, with the first patient dosed in March 2023, and plans to expand to China and the United States [1] - The tri-specific mechanism of CS2009 aims to enhance anti-tumor effects by integrating three validated targets, potentially surpassing existing therapies based on PD-(L)1 [1][2] Group 1 - CS2009 targets PD-1, VEGFA, and CTLA-4, showing promise in the treatment of solid tumors and the potential to replace current PD-(L)1-based therapies [2] - The combination of PD-1 and CTLA-4 blockade has demonstrated synergistic effects in various tumor types, significantly improving overall survival (OS) and progression-free survival (PFS) [1] - Further blocking of the VEGFA signaling pathway is expected to enhance the therapeutic efficacy of CS2009 [1]
基石药业(02616)重磅发布CS2009(PD-1/VEGF/CTLA-4)最新临床前研究结果